Life science members from a wide range of backgrounds have come together with business leaders and innovators from industry and universities at a partner showcase to highlight the work of the Oxford Academic Health Science Network (Oxford AHSN).
Approximately 40 people attended the event last Thursday (May 19th) which took place at the conference centre on Milton Park, Abingdon.
It was a chance for delegates to highlight the world-leading life science taking place in the Oxford region and to discuss the challenges and opportunities around this including investment, speeding up adoption, the challenges of developing new antibiotics and generating economic growth.
They were welcomed by Keith Errey, CEO of Isansys Lifecare, and Jon Harris, CEO of OBN.
Keith spoke about how Isansys is leading the way with a unique vision of digital health embodied in its Patient Status Engine, a remarkable new patient monitoring platform which collects and analyses patients’ vital signs and alerts doctors and nurses when a patient’s health is deteriorating.
He also emphasised the importance of collaboration in creating opportunities for innovators which will ultimately benefit patients.
Keith said: “We have long been associated with the Oxford AHSN and they are an organisation which recognises the power of what we’re doing and how it runs across a range of clinical sectors. It was with their help and support that we received Phase 1 and Phase 2 funding from Innovate UK through the SBRI programme and were able to transform our system from being ‘something interesting’ and turn it into a complete scaled system. Thanks to their help and support we are now being recognised by people around the world. This week we have shipped systems to Norway, Germany and India and demand for the systems has surpassed our expectations.
“At Isansys we are not just building and developing digital technology - we are creating a new class of data-driven biomarkers. A good example of this is the work we’re doing with hepatologists at the Royal Free Hospital in London where the data from just one wireless wearable sensor patch taken over a 20-minute period is equivalent to the data and information content that is traditionally obtained through a blood test that takes hours of lab time and requires the patient to attend the hospital. This is a major shift towards data-driven methods and we see a new paradigm emerging. ”
Professor Gary Ford, CEO of the Oxford AHSN, then set the scene with an overview of the breadth of collaborative work across the Oxford AHSN region.
This was demonstrated in the wide-ranging presentations given by senior executives of some of Oxford’s leading lifescience businesses including Peter Nolan, CBO of Oxford BioMedica, Dr Eliot Forster, CEO of Immunocore, Steve Harris, CEO of Circassia and Andy Varde, Director of Research & Development at Owen Mumford Ltd.
A short video from this showcase will be available shortly.
Copies of the three documents from Oxford AHSN, which were made available at the event, can be found online here:http://www.oxfordahsn.org/news-and-events/news/may-newsletter-full-of-news-and-opportunities/